H.C. Wainwright raised the firm’s price target on Dynavax (DVAX) to $31 from $29 and keeps a Buy rating on the shares. The company’s preliminary Q4 Heplisav-B sales were within guidance, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.